Friday, 19 Jul 2019

You are here

Diet and Weight Loss Improves Psoriatic Arthritis

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

Obesity is highly prevalent in psoriatic patients and is associated with higher disease activity, poorer effect of treatment and increased cardiovascular morbidity. 

VLED (640 kcal/day) was taken during 12–16 weeks, depending on pre-treatment BMI. Afterwards, an energy-restricted diet was gradually reintroduced. 

A total of 46 patients were enrolled and maintained on static treatment with conventional and/or biologic disease-modifying anti-rheumatic drugs from 3 months before, until 6 months after, baseline. 

A total 46 patients were enrolled and 41 completed the study; increased BMI at baseline was associated with higher disease activity and poorer function.

The median weight loss in the trial was 18.7 kg (IQR 14.6–26.5) or 18.6% of the baseline weight.

Disease parameters improved significantly after weight loss, including tender/swollen joint counts, CRP, BSA, Leeds enthesitis index, HAQ and patient VAS for global health, pain and fatigue.

Weight loss was associated with an increase in minimal disease activity (MDA) from 29 to 54%, (p = 0.002).

ACR 20, 50 and 70 responses were 51.2%, 34.1% and 7.3% respectively, at 6 months follow-up. A larger weight loss resulted in more improvement in a dose-response manner. The treatment was effective, safe and well tolerated.

These findings were underscored by recent dietary recommendations from the National Psoriasis Foundation.(Citation and

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Fatigue is Driven by Inflammation, Pain, and Chronicity in Psoriatic Arthritis

Correlates with fatigue were assessed in psoriatic arthritis (PsA) patients in the DANBIO registry and found to be associated with  clinical inflammatory factors, disease duration, and chronic pain.

A toital of 2062 PsA patients in the Danish nationwide registry DANBIO were studied by cross-sectional survey from December 2013 to June 2014.

CAM Use is Common in Psoriasis

The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.

The National Psoriasis Foundation commissioned a survey of patients on CAMs use and patients' perceptions.

The survey was sent to 100,927 NPF members and 219 completed it.

Recommendations for Exercise in Ankylosing Spondylitis

Australian researchers have assessed the problem of exercise in ankylosing spondylitis (AS). After posing 10 questions to 11 experts they have provided evidence and consensus-based ecommendations on exercise in AS.

Biologic Retention in Ankylosing Spondylitis Patients

A study of biologic-naïve patients with ankylosing spondylitis (AS) who started therapy with a tumour necrosis factor inhibitor (TNFi) shows that after 5 years only 46% are still on a TNFi and that some are able to lower the dose over time.

A nationwide Swedish Rheumatology register followed 2590 Bio-naïve AS who started a TNFi between 2006–2015.

Low Serious Infection Risk with Newer Agents in Psoriasis

JAMA Dermatology reports on a comparative cohort study of 107,707 psoriasis patients, finding a decreased risk of serious infections among users of apremilast, etanercept, and ustekinumab when compared with methotrexate.